Moreover, when administered in CXCR4+ tumor model, T22-GFP-H6 mostly accumulates in the tumor compared to other non-tumor bearing organs (Unzueta et al., 2012; Falgàs et al., 2020; Rioja-Blanco et al., 2022a). This evidence concerns the gene CXCR4 and neoplasm.